Current Projects

1.IDENTIFY Study – the Investigation and DEtection of urological Neoplasia in fast track paTIents reFerred with haematuria: a multicentre analYsis 
Lead Trainee
Mr Sinan Khadhouri

2. A multi-centre cohort study evaluating the role of inflammatory markers in patient’s presenting with acute ureteric colic
Lead Trainee
Mr Taimur Shah MBBS, BSc, MRCS
Urology SpR London
Research Fellow University College London

3. Systematic review on MRI-targeted prostate biopsy
Lead Trainee
Mr Veeru Kasivisvanthan
Urology SpR London
NIHR Doctoral Fellow, University College London

4. Peer Review Opportunities with the International Journal of Surgery (IJS), Annals of Royal College and European Journal of Surgical Oncology. 

If interested please email veeru.kasi@ucl.ac.uk with your CV attached.

5.  Systematic Review in Testicular Torsion 

6. British Journal Urology International (BJUI) / BURST Podcast Series

BURST are proud to be coordinating a BJUI / BURST podcast series summarising NICE guidance / updates. This is an outstanding opportunity for online publication for our members. If you are interested in completing a podcast for this series please click here for further information and email eleanor.zimmermann@nhs.net with your CV and preference of article you would like to feature in your podcast.

Completed Projects 

Investigating the relationship between pre-operative patient anxiety and intra-operative surgical outcomes

Lead Trainee
Dr Alastair Lamb, MBChB, PhD, FRCS(Urol)
Clinical Lecturer & Honorary Urology SpR
Academic Urology Group, University of Cambridge Dept of Surgery & CRUK Cambridge Institute

Got a good research idea?

Want to take it to the next level and start a national study? 

Its never too early to start planning your proposal for Dragons’ Den @ BAUS. We are looking to find research projects that could be led by you and undertaken by trainees across the UK.

The top three proposals will be selected for presentation at the BURST session at BAUS. Presenters will be given advice and constructive feedback to help turn a research question into reality.

The BURST Research Collaborative will support enthusiastic trainees and provide a network to allow the delivery of multi-centre clinical research/audit projects across the UK.

Keep an eye out for our announcement inviting proposals for Dragons Den @ BAUS 2019

Previous successful winners:


MIMIC (2016-2017): A Multi-centre cohort study evaluating the role of Inflammatory Markers In patient’s presenting with acute ureteric Colic 


IDENTIFY (2017-2018): The Investigation and DEtection of urological Neoplasia in paTIents reFerred with suspected urinary tract cancer: A multicentre analYsis

Abstracts will be scored by the BURST committee who will be looking at whether the study is designed well to answer the question, whether there is added value from trainee collaboration, the value to urological clinical practice, the value to the science of urology, as well as study clarity/style of presentation.

Please fill in the form at the link as follows by 1st May 2018


We look forward to seeing you in Liverpool.

Best wishes,

Veeru Kasi on behalf of the BAUS section of academic urology and BURST Research Collaborative

Job Adverts

We will advertise Urology Research Fellow / Clinical Fellow Job Opportunities for the new round as they come available.

If you would like a job posted here, please contact us.

Clinical Trials

Clinical trial participation

The BURST Research Collaborative would like to encourage its Urological Registrar members to actively participate in ongoing national clinical trials.  BURST is working in collaboration with the Clinical Trials and Statistics Unit at the Institute of Cancer Research (ICR-CTSU) in order to further the research opportunities for BURST members.
We would like to highlight some surgical urology trials that are relevant to our members and would encourage you to assist with patient identification in your current role.
For trainees working at a unit where the trial is open already but you would like to get involved in recruiting patients: 
Please discuss this with the principal investigator (PI) at your site to let them know that you are interested in recruiting patients for the study – they will usually be delighted that you have shown an interest. If you will be involved in approaching patients you will need to have Good Clinical Practice (GCP) training (half day online course), need to view the trial site initiation materials and be included on the trial delegation logs. Please contact the trial team using the details below if you need any advice on how to get involved.. If you are able to commit a lot of time to the success of the study at your site, you may ask your PI if he is willing to make you a Co-PI.
For trainees working at a unit where a trial is not open but you would like to participate:
If you are interested in supporting the setup and recruitment to one of these trials and be Co-PI on a study at your site, please discuss the trial with the most relevant Consultant Urologist/Clinician at your unit.  They would need to act as who agrees to be Principal Investigator and agree to oversee study conduct at your Trust.  Please contact the trial team using the details below if you need any advice on how to get involved or once you have identified a potential PI at your site to progress with site setup.
Information about where each trial is currently running and start and end dates can be found on the UK Clinical Trial Gateway: https://www.ukctg.nihr.ac.uk/home/
CALIBER (Non-muscle invasive bladder cancer)
CALIBER is randomised, multicentre, phase II feasibility study investigating whether intravesical MMC (chemoresection) could be a treatment option for people with recurrent low risk, non-muscle-invasive bladder cancer. Patients will either receive four once-weekly intravesical instillations of 40mg mitomycin C or standard surgical management in use at their hospital for treatment of recurrence. The trial objective is to demonstrate that chemoresection has sufficient activity against NMIBC to warrant further investigation of its role as a potential alternative to surgical intervention for low risk NMIBC recurrence.
Trial opened January 2015, planned recruitment period 2-3 years.
PHOTO (Non-muscle invasive bladder cancer)
PHOTO is a pragmatic, multicentre, randomised controlled phase III trial, investigating the efficacy of using photo-dynamic diagnosis (PDD) under blue light – instead of white light – for transurethral resection of bladder tumour (TURBT) in intermediate and high risk non-muscle invasive bladder cancer. PHOTO has two main objectives (1) Clinical effectiveness: compare time to recurrence, for each of the two treatment strategies, with a principal point of interest at 3 years. (2) Cost-effectiveness: evaluate cost-effectiveness by the incremental cost for recurrence avoided and cost-utility as the incremental cost per quality-adjusted life year (QALY) gained at three years.
Trial opened October 2014, planned recruitment period 3 years.
POUT (upper tract urothelial carcinoma)
POUT is a phase III, multicentre, randomised controlled trial to determine the efficacy, safety and effects on patients’ quality of life of adjuvant chemotherapy following radical nephro-ureterectomy for invasive upper tract urothelial carcinoma. POUT aims to determine whether adjuvant combination chemotherapy improves the disease-free survival for patients with resected histologically confirmed muscle invasive (pT2-T4, N0-3) or node positive upper tract urothelial carcinoma. Participants will either receive immediate platinum based combination chemotherapy (gemcitabine–cisplatin or gemcitabine–carboplatin) or be allocated to the surveillance group to be closely monitored for signs of recurrence, receiving appropriate treatment if disease returns.
Trial opened May 2012, planned recruitment period 7 years.
InPACT (penile carcinoma)
InPACT is an international phase III trial with a Bayesian design incorporating two sequential randomisations (InPACT-neoadjuvant and InPACT-pelvis) in patients with squamous carcinoma of the penis who have inguinal lymph node metastases (i.e. locally advanced disease). InPACT aims to determine: If there is a role for neoadjuvant therapy in this patient group; and If prophylactic pelvic lymph node dissection (PLND) improves survival in patients at high risk of recurrence following inguinal lymph node dissection (ILND).
Trial opened: March 2017, planned recruitment period 5 years.
PACE (localised prostate cancer)
PACE is a multicentre, international phase 3 randomised controlled study to assess whether hypofractionated stereotactic body radiotherapy (SBRT) offers therapeutic benefit over prostatectomy (PACE-A) or conventional radiotherapy (PACE-B) in men with early stage, organ-confined prostate cancer.
Trial opened: August 2012, planned recruitment period 8 years.

Trial Management Group




The Cancer Research UK funded Clinical Trials and Statistics Unit at the Institute of Cancer Research (ICR-CTSU) runs a portfolio of national and international phase III multicentre randomised controlled trials and phase II trials of targeted treatments, particularly for urological and breast cancer. The Unit is a UK Clinical Research Collaboration Registered CTU and an NCRI Cancer Clinical Trials Unit.


We have an opportunity for a Urology trainee registrar to join the Trial Management Group (TMG) of our multicentre urological clinical trials. The trials with currently available trainee positions are: CALIBER and POUT:
The TMG is a multidisciplinary committee responsible for overseeing the clinical, scientific and operational aspects of the trial. The TMG comprises the Chief Investigator (CI), co-investigators, key clinical and scientific collaborators, other key professionals involved in the conduct of the trial and ICR-CTSU representatives (including the trial statistical lead, the trial manager and trial statistician).
This position will provide a valuable insight into the ongoing management of multicentre clinical trials and a unique opportunity to further career development for a registrar with an interest in urological trials research.


The responsibilities of a TMG member include:
  • oversee the on-going conduct of the trial
  • provide clinical or other expert guidance to ICR-CTSU and participating sites
  • develop strategies to optimise recruitment
  • input into the monitoring and classification of serious adverse events (SAEs)
  • input into and critically review trial reports and related documentation as required
  • promote the trial and maintain the profile of the trial during its follow-up phase
  • bring to the attention of other members of the TMG any issues considered of relevance to the on-going conduct of the trial
  • contribute to presentation and publication of trial outcomes.


The duration of the appointment can be flexible but a minimum commitment of 1 year is expected.
You will be required to attend 1 day in person at the London-based ICR-CTSU for a training session on the assigned clinical trial. You will be required to attend TMG meetings (which are scheduled more than 6 weeks in advance) approximately twice a year, though the option to join by telephone is available. TMG meetings last around 1.5 – 2 hours. You will be required to read and respond to email correspondence throughout the year, which may require your clinical review.
Members will be reimbursed for reasonable travel and other expenses incurred in accordance with ICR Administrative Procedures. This position offers no other financial remuneration.


You may contact ICR-CTSU for further information by emailing Steven.Penegar@icr.ac.uk

Previous opportunities

CLOSED: Clinical Lecturer in Urology: University of Glasgow
CLOSED: Would you like to be an investigator collecting patient data for the national MIMIC study?
Please contact: taimur.shah@doctors.org.uk
CLOSED: Clinical Research Fellow in Urology 1: Imperial College London
CLOSED: Clinical Research Fellow in Urology 2: Imperial College London